Published
September 27, 2026
Investors who bought or otherwise acquired Edwards Lifesciences (NYSE: EW) common stock between February 6, 2024 and July 24, 2024 may qualify to claim a pro rata share of a $39 million Edwards Lifesciences securities class action settlement, estimated at about $0.66 a share before fees. Claims close December 2, 2026, and the final approval hearing is set for December 16, 2026.
Current Status
Claims are open. Claim forms are due December 2, 2026, whether filed online or mailed with a postmark by that date. The court granted preliminary approval on August 3, 2026, and the final approval hearing is scheduled for December 16, 2026 at 1:30 p.m. Pacific Time. No payment date has been announced; distributions come only after final approval, the resolution of any appeals and the completion of claims processing.Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
Status
Claims Open
Claim Deadline
December 2, 2026
Estimated Payout
~$0.66 a share
average before fees · pro rata share of $39M
Proof Required
Yes
brokerage statements or trade confirmations
What Changed Recently?
The claim process opened after Judge Anne Hwang of the U.S. District Court for the Central District of California preliminarily approved the $39,000,000 settlement on August 3, 2026, and the court-ordered notice went out under an order dated August 24, 2026. The case, Patel v. Edwards Lifesciences Corp., No. 8:24-cv-02221, was filed on October 14, 2024.Investors in the case allege that Edwards and its chief executive, Bernard J. Zovighian, made materially false and misleading statements about the growth prospects of the company's transcatheter aortic valve replacement (TAVR) business, the heart-valve platform at the center of Edwards' sales. The alleged truth came out on July 24, 2024, when Edwards reported results and revised its TAVR guidance; the plan of allocation measures the stock's reaction on July 25, 2024. Edwards and Zovighian deny all of the allegations and deny violating the securities laws, and the settlement is not an admission of wrongdoing.
On September 19, 2025, the court let the core Section 10(b) fraud claim proceed against Edwards and Zovighian while dismissing claims against three other former executives, calling the question of Zovighian's intent "a very close one." After discovery limited to that issue, the parties accepted a mediator's recommendation of $39 million following an April 20, 2026 session and signed the settlement agreement on July 1, 2026.
Who Qualifies?
The settlement class covers every person or entity that purchased or otherwise acquired Edwards Lifesciences common stock from February 6, 2024 through July 24, 2024, inclusive, and was damaged by it. Edwards traded on the New York Stock Exchange under the ticker EW.Excluded are the defendants, Edwards' past and current executive officers and directors (including the three former individual defendants), their immediate family members, entities they control, their legal representatives and heirs, and anyone who opts out.
Two practical limits narrow who actually recovers. First, shares have to have been held through the close of trading on July 24, 2024; a share bought and sold inside the class period recovers nothing. Second, Edwards stock held through an Edwards employee benefit plan covered by ERISA is left off this claim — only shares bought outside the plan count. Option contracts are not eligible, and short sales carry no recoverable loss.
How Much Can You Get?
The notice estimates an average recovery of about $0.66 per eligible share before court-approved fees and expenses. If the court awards the maximum fees and expenses, those deductions average about $0.17 a share, which would leave roughly $0.49 a share. Both numbers are estimates that assume every eligible investor files; actual payments depend on when you bought and sold, the prices you paid, and how many valid claims come in.Lead Counsel will ask for attorneys' fees of up to 25% of the settlement fund and up to $195,000 in litigation expenses. Notice and administration costs also come out of the fund before the net amount is divided.
The proposed plan of allocation assigns each eligible share a "Recognized Loss Amount" based on $24.17 of estimated artificial inflation removed from the price on July 25, 2024:
- Sold before the close on July 24, 2024: $0.
- Sold from July 25, 2024 through October 22, 2024: the smallest of $24.17, the purchase price minus the average closing price from July 25 through the sale date, or the purchase price minus the sale price.
- Still held at the close on October 22, 2024: the lesser of $24.17 or the purchase price minus $66.77, the average closing price during the 90-day look-back period.
Multiple trades are matched last in, first out. A claimant with an overall market gain on class-period Edwards shares recovers nothing, and a claimant whose market loss is smaller than the calculated claim is capped at that market loss. The net fund is then split pro rata, and any payment that calculates to less than $10 is not issued.
What Proof or Notice ID Is Required?
Yes, proof is required. The claim form asks for a schedule of your Edwards common stock holdings and transactions, supported by documentation such as brokerage account statements or trade confirmations. The parties and the administrator do not have your trading records, so keep every statement showing your Edwards purchases, sales and holdings for the period.If your broker or another nominee bought shares on your behalf, the notice requires that nominee to forward the notice or send your contact details to the administrator.
What Is the Deadline?
Claim forms must be submitted online by December 2, 2026, or mailed with a postmark no later than December 2, 2026. The notice does not specify a time zone for online filing.Requests for exclusion must be received by December 2, 2026. Written objections to the settlement, the plan of allocation or the fee request must be filed with the court and received by counsel by December 2, 2026. Lead Counsel's fee motion is due November 11, 2026 and will be posted on the settlement website.
How Do You Take Action?
File on the official Edwards Lifesciences Securities Litigation website, which is run by the court-approved administrator, Kroll Settlement Administration. Choose the claim form, enter your identifying information, list every Edwards common stock purchase, acquisition and sale from February 6, 2024 through October 22, 2024 along with your holdings at the start of the class period, and upload your supporting statements. A paper claim form can also be downloaded from the same site and mailed.To opt out instead, the notice requires a signed written request that names this case, lists your Edwards holdings and class-period trades, and reaches the administrator by December 2, 2026. Opting out means no payment but keeps your right to sue separately.
What Happens Next?
Judge Hwang will hold the final approval hearing on December 16, 2026 at 1:30 p.m. Pacific Time in Courtroom 9C of the federal courthouse in Los Angeles. The notice warns that the date or format can change without further mailed notice and that any change will be posted on the settlement website. The court will decide whether to approve the settlement, the plan of allocation and the fee request; payments follow only after final approval, any appeals and the completion of claims processing.Sources and Verification
- Edwards Lifesciences Securities Litigation — official settlement website maintained by Kroll Settlement Administration
- Notice of Pendency of Class Action and Proposed Settlement (dated August 24, 2026), including the Plan of Allocation
- Patel v. Edwards Lifesciences Corp., No. 8:24-cv-02221 (C.D. Cal.) — docket on Justia
- Bernstein Litowitz Berger & Grossmann — Lead Counsel's case page
- Law360 — report on the motion for preliminary approval
Questions
I bought Edwards stock during the class period but sold it before July 25, 2024. Do I get anything?
No. Under the proposed Plan of Allocation, shares bought during the class period and sold before the close of trading on July 24, 2024 have a Recognized Loss of $0. Only shares still held when the market closed on July 24, 2024 can produce a recovery.
Can I claim for Edwards shares held in my company 401(k) or other Edwards employee benefit plan?
No. The notice tells participants in an Edwards ERISA-covered employee benefit plan to leave plan shares off the claim form and list only Edwards common stock bought outside the plan.
Do Edwards stock options count?
Option contracts themselves are not eligible securities. If you bought or sold Edwards common stock by exercising an option, the exercise date and exercise price are treated as the purchase or sale date and price for that stock.
Is there a minimum payment in the Edwards Lifesciences settlement?
Yes. If a claimant's calculated distribution comes to less than $10.00, no payment is made to that claimant, and the money is redistributed to claimants whose distribution is $10.00 or more.
Does the Edwards settlement release derivative or ERISA claims?
No. The release carves out claims in any related ERISA or shareholder derivative action, including In re Edwards Lifesciences Corp. Derivative Litigation, No. 8:24-cv-02822 (C.D. Cal.).
Official Settlement Notice
For more class actions keep scrolling below.
Settlement Amount
$39,000,000
Case Title
Patel v. Edwards Lifesciences Corp.
Case Number
8:24-cv-02221-AH-KES
Court
U.S. District Court, Central District of California
Final Approval Hearing
December 16, 2026 at 1:30 PM PT
Judge Anne Hwang · Courtroom 9C, Los Angeles
Administrator
Kroll Settlement Administration
Official Website
Edwards Lifesciences Securities Litigation
